N-(4-methyloxazo-2-yl)-N'-phenylurea | 97600-15-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methyloxazo-2-yl)-N'-phenylurea
• 英文别名: 1-(4-Methyl-1,3-oxazol-2-yl)-3-phenylurea
• CAS: 97600-15-2
• 化学式: C₁₁H₁₁N₃O₂
• 分子量: 217.227
• InChiKey: GQCIMIKGVDTZPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异氰酸苯酯 、 2-氨基-4-甲基-噁唑 以 甲苯 为溶剂， 反应 24.0h， 以52%的产率得到N-(4-methyloxazo-2-yl)-N'-phenylurea
  参考文献：
  名称：

  Crank, George; Khan, Humaid R., Australian Journal of Chemistry, 1985, vol. 38, # 3, p. 447 - 458

  摘要：

  DOI：

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2017015451A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式（I），或其药用可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物能够抑制由乙型肝炎病毒（HBV）编码的蛋白质，或干扰乙型肝炎病毒的生命周期功能，同时也可作为抗病毒药物使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170022150A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A 1 -Y-A 2 -Z-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的化学式（I），或其药学上可接受的盐、酯或前药：X-A1-Y-A2-Z-L-R（I），这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于给患有HBV感染的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• CRANK, G.;KHAN, H. R., AUST. J. CHEM., 1985, 38, N 3, 447-458
  作者：CRANK, G.、KHAN, H. R.

  DOI：——

  日期：——
• Hepatitis B Antiviral Agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160332996A1

  公开（公告）日：2016-11-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• Crank, George; Khan, Humaid R., Australian Journal of Chemistry, 1985, vol. 38, # 3, p. 447 - 458
  作者：Crank, George、Khan, Humaid R.

  DOI：——

  日期：——